Trends in oral and vaginally administered estrogen use among US women 50 years of age or older with commercial health insurance

被引:28
作者
Weissfeld, Joel L. [1 ]
Liu, Wei [1 ]
Woods, Corinne [1 ]
Zhang, Rongmei [2 ]
Li, Jie [1 ]
van der Vlugt, Theresa H. [3 ]
Slaughter, Shelley R. [3 ]
机构
[1] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA
[2] US FDA, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
[3] US FDA, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2018年 / 25卷 / 06期
关键词
Drug administration routes; Drug utilization; Estrogen therapy; United States; POSTMENOPAUSAL HORMONE-THERAPY; UNITED-STATES; PLUS PROGESTIN;
D O I
10.1097/GME.0000000000001054
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: We aimed to provide information through 2015 about use in the United States of estrogen products, including orally and vaginally administered products, in postmenopausal women. Methods: We used prescription claims for US commercial health insurance to calculate, in women 50 years of age or older (n = 12,007,364), the age-standardized and age-specific annual prevalence of estrogen use, by formulation and route of administration, for the period 2006 through 2015. Results: The age-standardized annual prevalence of a prescription claim for oral estrogens declined over time, from 83 per 1,000 women in 2007 to 42 per 1,000 women in 2015. The age-standardized annual prevalence of a prescription claim for vaginal estrogens peaked in 2011, at 42 per 1,000 women, before declining to 35 per 1,000 women in 2015. The age-standardized annual prevalence of a prescription claim for transdermal estrogen fluctuated between 15 and 17 per 1,000 women. In age groups under 65 years of age, annual prevalence rates for vaginal rings and inserts declined over the latter half of the study period. Conclusions: Analyses of US prescription claims data between 2006 and 2015 for women 50 years of age or older showed declining use of oral estrogen generally and vaginally administered estrogen products specifically in age groups less than 65 years of age.
引用
收藏
页码:611 / 614
页数:4
相关论文
共 19 条
[1]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[2]  
[Anonymous], 2016, IMS HLTH REAL WORLD
[3]  
Center for Drug Evaluation and Research, 2015, FDA DRAFT GUID IND N
[4]   Evolution of postmenopausal hormone therapy between 2002 and 2009 [J].
Ettinger, Bruce ;
Wang, Sharon M. ;
Leslie, R. Scott ;
Patel, Bimal V. ;
Boulware, Michael J. ;
Mann, Mark E. ;
McBride, Michael .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2012, 19 (06) :610-615
[5]   National use of postmenopausal hormone therapy - Annual trends and response to recent evidence [J].
Hersh, AL ;
Stefanick, ML ;
Stafford, RS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (01) :47-53
[6]   From systemic hormone therapy to vaginal estrogen - A nationwide register study in Finland, 2003-2012 [J].
Holm, Elisa ;
Aaltonen, Katri ;
Heikkinen, Anna-Mari ;
Tiihonen, Miia .
MATURITAS, 2014, 78 (04) :293-297
[7]  
Howden LM, US CENSUS BRIEFS ISS
[8]   Trends of Postmenopausal Estrogen Plus Progestin Prevalence in the United States Between 1970 and 2010 [J].
Jewett, Patricia I. ;
Gangnon, Ronald E. ;
Trentham-Dietz, Amy ;
Sprague, Brian L. .
OBSTETRICS AND GYNECOLOGY, 2014, 124 (04) :727-733
[9]   Use of postmenopausal hormone therapy since the Women's Health Initiative findings [J].
Kelly, JP ;
Kaufman, DW ;
Rosenberg, L ;
Kelley, K ;
Cooper, SG ;
Mitchell, AA .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (12) :837-842
[10]   Reviewing the options for local estrogen treatment of vaginal atrophy [J].
Lindahl, Sarah H. .
INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2014, 6 :307-312